Konruns(SH:603590) Xin Lang Zheng Quan·2025-09-17 06:17Core Viewpoint - Kangchen Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 155.22%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - On September 17, Kangchen Pharmaceutical's stock price decreased by 2.04%, closing at 58.50 CNY per share, with a trading volume of 165 million CNY and a turnover rate of 1.76% [1]. - The company's total market capitalization is 9.322 billion CNY [1]. - Year-to-date, the stock has risen by 155.22%, with a 12.13% increase over the last five trading days, an 8.35% increase over the last 20 days, and an 81.96% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Kangchen Pharmaceutical reported a revenue of 461 million CNY, representing a year-on-year growth of 13.79% [2]. - The net profit attributable to shareholders for the same period was 91.046 million CNY, reflecting a year-on-year increase of 14.95% [2]. Group 3: Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders decreased by 10.82% to 9,970, while the average circulating shares per person increased by 12.14% to 15,771 shares [2]. - The company has distributed a total of 437 million CNY in dividends since its A-share listing, with 175 million CNY distributed over the past three years [3]. - Notable institutional shareholders include Penghua Medical Technology Stock A, which increased its holdings by 35.46% to 1.3944 million shares, and new entrants like E Fund Healthcare Industry Mixed A and CITIC Securities Medical Reform A [3].